Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meera Mohan

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Haematologica|August 30, 2023
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myelomaLindsay Hammons, Aniko Szabo, Abhishek Janardan, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
Transplantation and Cellular Therapy|June 13, 2024
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in MyelomaWilliam Wesson, Danai Dima, Nahid Suleman, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
Blood Cancer Journal|April 23, 2025
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myelomaMeera Mohan, Aniko Szabo, Heloise Cheruvalath, et al.
Bone Marrow Transplantation|February 16, 2024
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myelomaMeera Mohan, Aniko Szabo, Anannya Patwari, et al.
Journal of Clinical Medicine|March 25, 2022
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital AdmissionKristin Larsen, Horace Spencer, Meera Mohan, et al.
British Journal of Haematology|August 28, 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodiesOthman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, et al.
Contemporary Clinical Trials Communications|September 2, 2025
Mindfulness vs. sleep education during autologous hematopoietic cell transplantation for multiple myeloma: Feasibility of a randomized controlled pilot studyElisabeth C Henley, Hannah A Liphart, Keayra J Morris, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Haematologica|August 30, 2023
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myelomaLindsay Hammons, Aniko Szabo, Abhishek Janardan, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
Transplantation and Cellular Therapy|June 13, 2024
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in MyelomaWilliam Wesson, Danai Dima, Nahid Suleman, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
Blood Cancer Journal|April 23, 2025
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myelomaMeera Mohan, Aniko Szabo, Heloise Cheruvalath, et al.
Bone Marrow Transplantation|February 16, 2024
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myelomaMeera Mohan, Aniko Szabo, Anannya Patwari, et al.
Journal of Clinical Medicine|March 25, 2022
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital AdmissionKristin Larsen, Horace Spencer, Meera Mohan, et al.
British Journal of Haematology|August 28, 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodiesOthman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, et al.
Contemporary Clinical Trials Communications|September 2, 2025
Mindfulness vs. sleep education during autologous hematopoietic cell transplantation for multiple myeloma: Feasibility of a randomized controlled pilot studyElisabeth C Henley, Hannah A Liphart, Keayra J Morris, et al.
Pageof 7